How will these field-trial studies differ from those being conducted in routine clinical settings? The aims of the two field-trial designs are largely the same: to determine whether the proposed changes are acceptable to clinicians and patients, whether they are stable over time and among different clinicians, and whether they improve diagnosis as well as aspects of treatment planning (for example, whether changes in the treatment plan are made in response to data collected on the severity of a patient's symptoms). In both designs, patients will be interviewed using diagnostic checklists to help clinicians assess all DSM-5 proposed criteria. Patients and clinicians will also complete measures to assess potential symptoms that patients frequently endorse, as well as the severity of symptoms they are currently experiencing. However, greater staffing and resources in these larger field-trial sites will allow us to assess patients on three visits, rather than the two visits utilized in the routine clinical-setting design. This means more data can be collected over longer periods, allowing us to observe how a patient's symptoms may change (or not change, as the case may be) over time. Furthermore, these sites permit us to include additional clinicians, which helps us determine whether different practitioners will arrive at the same diagnosis when assessing the same patient.